Expression of Early Growth Response Gene-2 and Regulated Cytokines Correlates with Recovery from Guillain–Barré Syndrome
Authors:
- Ernesto Doncel-PérezErnesto Doncel-Pérez
- Lourdes Mateos-HernándezLMLourdes Mateos-Hernández
- Eduardo ParejaEPEduardo Pareja
- Margarita VillarMVMargarita Villar
- Raquel TobesRTRaquel Tobes
- Virginia Vila del SolVSVirginia Vila del Sol
- Ricardo RamosRRRicardo Ramos
- Isabel G. Fernández de MeraIMIsabel G. Fernández de Mera
- José de la FuenteJosé de la Fuente
Open Access
- 1 February 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 196 (3) , 1102-1107
Abstract
Guillain–Barré syndrome (GBS) is an immune-mediated peripheral neuropathy. The goal of this research was the identification of biomarkers associated with recovery from GBS. In this study, we compared the transcriptome of PBMCs from a GBS patient and her healthy twin to discover possible correlates of disease progression and recovery. The study was then extended using GBS and spinal cord injury unrelated patients with similar medications and healthy individuals. The early growth response gene-2 (EGR2) was upregulated in GBS patients during disease recovery. The results provided evidence for the implication of EGR2 in GBS and suggested a role for EGR2 in the regulation of IL-17, IL-22, IL-28A, and TNF-β cytokines in GBS patients. These results identified biomarkers associated with GBS recovery and suggested that EGR2 overexpression has a pivotal role in the downregulation of cytokines implicated in the pathophysiology of this acute neuropathy.Keywords
This publication has 27 references indexed in Scilit:
- Elevated Levels of Cerebrospinal Fluid and Plasma Interleukin-37 in Patients with Guillain-Barré SyndromeMediators of Inflammation, 2013
- Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating BatfThe Journal of Immunology, 2013
- IL-17 and IL-22 in Cerebrospinal Fluid and Plasma Are Elevated in Guillain-Barré SyndromeMediators of Inflammation, 2012
- Emerging drugs for Guillain-Barré syndromeExpert Opinion on Emerging Drugs, 2010
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- Antiganglioside antibodies and their pathophysiological effects on Guillain-Barre syndrome and related disorders--A reviewGlycobiology, 2009
- The Guillain–Barré syndrome: a true case of molecular mimicryTrends in Immunology, 2004
- Guillain-Barr?? SyndromeDrugs, 2004
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 gangliosideAnnals of Neurology, 2001